Showing results (91-100 of 143) with videos related to
Sort By:
Pageof 15
Thrombosis Research|February 22, 2024
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemiaGiovangiacinto Paterno, Raffaele Palmieri, Cristiano Tesei, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2015
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid LeukemiaDaniela F Angelini, Tiziana Ottone, Gisella Guerrera, et al.The Lancet. Oncology|October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines CommitteeJaime Sanz, Gesine Bug, Fabio Ciceri, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional DatabaseMaria Teresa Voso, Susanna Fenu, Roberto Latagliata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, et al.Haematologica|August 2, 2007
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective studyMichele Baccarani, Daniela Cilloni, Michela Rondoni, et al.American Journal of Hematology|November 8, 2014
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Alfonso Piciocchi, et al.Annals of Hematology|June 14, 2014
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatmentMichele Dal Bo, Maria Ilaria Del Principe, Federico Pozzo, et al.Annals of Hematology|April 23, 2014
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphomaMaria Ilaria Del Principe, Francesco Buccisano, Mariagiovanna Cefalo, et al.Frontiers in Immunology|February 3, 2022
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical ImplicationsMarco Iannetta, Doriana Landi, Gaia Cola, et al.Pageof 15